证券日报网讯1月29日，惠泰医疗在互动平台回答投资者提问时表示，公司目前通过经销模式向欧盟市 场销售血管介入及部分电生理标测耗材产品，相关产品已获CE认证，该市场收入占公司整体营收比例 较低。 ...

【中标合同】 金螳螂(002081.SZ)：联合体中标梅园地块建设项目新建酒店部分室内精装修工程及弱电智能化工程 | | | 1月27日重要公告精选 | | --- | --- | --- | | 类型 | 公司 | 主要内容 | | 热点 | 华兰疫苗 | 尚无预防尼帕病毒相关的疫苗产品 | | | 天奇股份 | 参与银河通用机器人融资,获得银河通用机器人不高于0.38%股权 | | 项目投资 | 艾森股份 | 拟20亿元投建集成电路材料华东制造基地项目 | | 合同中标 | 北新路桥 | 中标12.21亿工程项目 | | 股权转让 | 永鼎股份 | 预计2025年度净利润同比增加225.66%到388. 48% | | 业绩预告 | 璞奏来 | 拟2.4亿元收购乳源氟树脂5%股权 | | 回购 | 惠泰医疗 | 累计回购0.7202%公司股份 | | 增减持 | 达意降 | 乐丰投资拟减持不超过3%股份 | | 其他 | 东材科技 | 实际控制人、副董事长熊海涛被留置 | | | 毅昌科技 | 实际控制人熊海涛被立案调查并实施留置 写 防隆に | 【热点】 天奇股份(002009.SZ)：参与银河通用机器 ...

从回购实施进展来看，恒瑞医药、京基智农、兴发集团回购金额最高，分别回购6.05亿元、9446.39万 元、6554.25万元。 从已完成回购来看，惠泰医疗、锡业股份、奥普科技已完成回购金额最高，分别回购2.5亿元、700.53万 元、85.0万元。 （文章来源：每日经济新闻） 每经AI快讯，Wind数据显示，1月28日，14家公司共发布15个股票回购相关进展。其中，2家公司首次 披露股票回购预案，4家公司回购方案获股东大会通过，4家公司披露股票回购实施进展，4家公司回购 方案已实施完毕。 从首次披露回购预案来看，格林美、达威股份分别拟回购不超303.26万元、23.21万元。 从股东大会通过回购预案来看，新开源、广东鸿图、广济药业回购金额最高，分别拟回购不超5000.0万 元、1809.51万元、42.13万元。 ...

每经AI快讯，惠泰医疗1月27日晚间发布公告称，截至本公告披露日，公司已通过上海证券交易所系统 以集中竞价交易方式累计回购公司股份约102万股，占公司总股本约1.41亿股的比例为0.7202%，回购成 交的最高价为264.27元/股，最低价为231元/股，支付的资金总额为人民币约2.5亿元，本次回购方案实 施完毕。 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每日经济新闻 每经头条（nbdtoutiao）——国际金价冲破5000美元！7年涨了280%，什么时候才见顶？专家：关键还 看美元，重点关注国际货币体系、降息和科技革命 （记者 王晓波） ...

证券代码：688617 证券简称：惠泰医疗 公告编号：2026-002 深圳惠泰医疗器械股份有限公司 关于股份回购实施结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/12/10，由公司董事会提议 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 日~2026 月 2025 9 | 12 | 月 | 年 | 10 | 日 8 | | 预计回购金额 | 2亿元~2.5亿元 | | | | | | | 回购价格上限 | 315元/股 | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | | □用于转换公司可转债 | | | | | | | | □为维护公司价值及股东权益 | | | | | | | 实际回购股数 | 1,015,738股 | | | | | | | 实际回购股数占总股本比例 | 0.7202 ...

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5] Core Views - The pharmaceutical sector underperformed the overall market, with a 0.39% decline in the biopharmaceutical sector compared to a 1.17% increase in the total A-share market [32] - The TTM price-to-earnings ratio for the pharmaceutical sector is 38.51x, which is at the 84.35th percentile of the historical valuation over the past five years [32][37] - The report highlights a shift in fund holdings, with a decrease in the proportion of pharmaceutical holdings in both pharmaceutical and non-pharmaceutical funds [11][16] Summary by Sections Market Performance - The overall A-share market increased by 1.17%, while the Shanghai and Shenzhen 300 index decreased by 0.62% [32] - The biopharmaceutical sector's performance was weaker than the overall market, with specific declines in chemical pharmaceuticals (-1.11%) and medical services (-2.17%) [32] Fund Holdings Analysis - As of Q4 2025, the net asset value of pharmaceutical funds reached 358.4 billion, a decrease of 9.0% from the previous quarter [11] - The proportion of pharmaceutical holdings in all funds was 7.97%, down 1.71 percentage points [16] - The largest sub-sectors by holdings were chemical preparations (37.5%) and other biological products (20.8%) [19] Company Earnings Forecasts and Ratings - Key companies such as Mindray Medical (237 billion market cap, "Outperform" rating) and WuXi AppTec (293.6 billion market cap, "Outperform" rating) are highlighted for their strong earnings forecasts [4] - The report lists several companies with projected earnings growth, including Aier Eye Hospital and New Industry, both rated "Outperform" [4] Investment Strategy - The report recommends focusing on innovative drugs and the CXO sector, emphasizing the competitive advantages of Chinese companies in the chemical CDMO space [41] - A portfolio of recommended stocks includes Mindray Medical, WuXi AppTec, and Aier Eye Hospital, among others [42][43]

内容概要：冠脉通路器械是经皮冠状动脉介入手术的必备耗材，其性能直接影响手术成效与并发症控制 水平。政策端，我国出台集采、创新审批、基层医疗建设等系列政策，从多维度为行业高质量发展筑牢 基础。需求端，全球及中国冠状动脉疾病患病人数稳步增长，2024年全球患者达2.2亿人、中国达2787.9 万人，且中国PCI手术渗透率与发达国家差距显著，为行业提供广阔增量空间。市场规模方面，全球冠 脉球囊扩张导管市场持续扩容，功能性球囊增速领先；中国市场呈"结构调整与高速增长并存"特征，通 用球囊受集采影响经历阶段性调整后有望回升，功能性球囊作为国产替代核心赛道增长迅猛，2024- 2028年复合年均增长率高达19.28%。竞争格局上，行业呈梯队化分布，外资主导高端市场，国产头部 企业加速突围，2024年国产冠脉球囊市场份额已达54.9%。未来，行业将沿着技术升级、国产替代深 化、基层市场扩容三大方向演进，形成"器械+服务+数据"的协同生态，驱动行业向创新普惠方向发 展。 上市企业：微创医疗（00853）、业聚医疗（06929）、乐普医疗（300003）、赛诺医疗（688108）、惠 泰医疗（688617）、蓝帆医疗（0023 ...

Summary of China Healthcare Industry Conference Call Industry Overview - **Industry**: China Healthcare Industry - **Report Date**: January 21, 2026 - **Sentiment**: Cautiously optimistic outlook for 2026 regarding hospital capital expenditures and market dynamics [1][2] Key Insights Capital Expenditure Trends - **Stable to Moderate Growth**: Hospital capital expenditures are expected to remain stable with moderate growth in 2026 [2] - **Survey Results**: 59% of surveyed hospital managers anticipate capital expenditure growth in 2026, up from 43% in late 2024, but still below 85% in late 2023 [3] - **Projected Growth Rate**: Expected capital expenditure growth of 4.7% in 2026, compared to 3.0% growth anticipated for 2025 [3] - **Actual Growth Expectations**: Respondents expect actual capital expenditure growth of 5.8% for 2025, indicating limited visibility on actual demand [3] Key Drivers of Expenditure - **Primary Drivers**: 1. Hospital Surplus (69%) 2. Patient Demand (50%) 3. Local Fiscal Budgets (44%) [3] - **Service Volume Constraints**: Factors such as Diagnosis-Related Group (DRG) payment limits and medical insurance settlements are seen as major constraints on service volume [3] Equipment and Technology Focus - **Investment Priorities**: Hospitals are prioritizing investments in AI, endoscopy, and imaging equipment, with a focus on surgical and flexible endoscopes, followed by CT and ultrasound [3] - **Weak Demand**: In vitro diagnostics are expected to remain weak [3] Company-Specific Insights Beneficiaries of Capital Expenditure Growth - **Mindray Medical (300760.SZ)**: Expected to benefit from a stable capital expenditure environment, with anticipated single-digit revenue growth in 2026. The company is expected to maintain a 16% share of planned capital expenditures [4][10] - **United Imaging (688271.SS)**: Anticipated to benefit from strong demand in high-end imaging, with projected revenue growth of approximately 21% in 2026 [4][11] - **New Industries (300832.SZ)**: Expected to face continued pricing pressure in in vitro diagnostics but may achieve above-industry growth due to healthy demand for chemical luminescence analyzers [4][12] - **Huatai Medical (688617.SS)**: Positioned to capitalize on the growing adoption of pulse field ablation technology, with projected revenue growth of 30% in 2026 [4][13] - **Guichuang Tongqiao (2190.HK)**: Expected to see revenue growth of around 30% driven by increased demand for neurointerventional and peripheral interventional procedures [4][15] Challenges for Global Players - **GE Healthcare**: Faces mixed impacts from increased capital expenditure and growing preference for local brands, which may offset some growth [4][16] - **Siemens Healthineers (SHL)**: Cautious outlook due to slow recovery in utilization rates and increased pricing pressure from procurement policies [4][17] - **Philips (PHIA)**: Similar cautious outlook with potential declines in market share for CT and ultrasound equipment [4][18] - **Olympus (7733.T)**: Expected to face challenges in maintaining market share in the digestive endoscopy market [4][19] - **Hologic (6869.T)**: Anticipated slowdown in clinical testing volumes and potential market share decline in hematology [4][20] Additional Observations - **Market Dynamics**: The report highlights a complex landscape for global medical technology companies in China, with both opportunities and pressures from local competition and procurement policies [4][16][17][18][19][20] - **Emerging Trends**: The shift towards local brands and the impact of procurement policies are significant trends that may reshape the competitive landscape in the healthcare sector [4][16][17][18][19][20]

Core Viewpoint - The medical device sector experienced a rise of 0.54% on January 21, with N Aisheren leading the gains, while the Shanghai Composite Index increased by 0.08% and the Shenzhen Component Index rose by 0.7% [1] Group 1: Stock Performance - N Aisheren (code: 920050) closed at 44.04, with a remarkable increase of 175.59% and a trading volume of 141,600 shares [1] - Tianzhihang (code: 688277) saw a rise of 12.38%, closing at 23.88 with a trading volume of 376,500 shares [1] - Xishan Technology (code: 688576) increased by 11.18%, closing at 76.80 with a trading volume of 34,000 shares [1] - Kangzhong Medical (code: 688607) rose by 10.91%, closing at 59.67 with a trading volume of 76,200 shares [1] - Shuoshi Biological (code: 6658889) increased by 9.74%, closing at 84.84 with a trading volume of 70,300 shares [1] Group 2: Capital Flow - The medical device sector saw a net inflow of 300 million yuan from institutional investors, while retail investors experienced a net outflow of 430 million yuan [2] - Major stocks like Sainuo Medical (code: 688108) had a net inflow of 69.18 million yuan from institutional investors, but a net outflow of 44.76 million yuan from retail investors [3] - LePu Medical (code: 300003) had a net inflow of 48.54 million yuan from institutional investors, with a slight net inflow of 0.52 million yuan from retail investors [3]

Group 1 - The core viewpoint of the news highlights the positive performance of the medical device sector, with significant stock price increases for various companies and a favorable market outlook driven by new pricing policies and international trade initiatives [1][2][3] Group 2 - As of January 21, the Shanghai Composite Index rose by 0.22%, while the medical device index increased by 0.69%, with notable stock performances from Tianzhihang-U (+13%), Sanyou Medical (+7%), and others [1] - The medical device ETF (562600) saw a 0.77% increase, with a trading volume of 254.268 billion yuan and a turnover rate of 4.15%. Over the past six months, the fund has gained 4.80%, and 11.30% over the past year [1] Group 3 - On January 20, the National Healthcare Security Administration issued guidelines for pricing medical services related to surgical robots and remote surgeries, establishing a structured pricing system to enhance innovation returns and improve accessibility to precision medicine [2] - A special seminar was held on January 17 to discuss how to leverage the medical device procurement and pricing platform to support the international expansion of Chinese medical devices, with plans for a cross-border channel based on procurement platforms in Guangxi and Tianjin [2] Group 4 - Multiple authoritative institutions have expressed optimism about the medical device sector, with expectations for a turning point in operations by 2026 due to optimized procurement rules and significant growth potential in domestic and international markets for surgical robots and AI medical technologies [3] - The medical device ETF (562600) tracks the CSI All Index for medical devices, with the top ten weighted stocks accounting for 45.04% of the total, including major players like Mindray Medical and United Imaging [3]